JAKARTA - PT Itama Ranoraya Tbk (IRRA) has allocated capital expenditures of up to IDR 300 billion to enter the manufacturer, clinical laboratory, and e-health service business. This was conveyed by Heru Firdausi Syarif, President Director of PT Itama Ranoraya Tbk (IRRA) in a press release quoted on Thursday (6/5).
He conveyed that the capital expenditure budget has increased compared to last year's IDR 25 billion. Next year, the company will still allocate a large enough capital expenditure for the company's needs.
According to him, the realization of the business plan will show results in 2022. The company's business growth this year will still come from the existing business. "This year, the growth target is around 80 to 100 percent or last year's business growth position," he said.
He said the sources of capital expenditure came from bank loans, issuance of debt securities and use of treasury shares. IRRA management, he said, had received approval from shareholders to obtain loans from banks. (LK/LM)